PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29617457-3	2018	In humans and rodents with cerebral ischemia/reperfusion (I/R), the SUR1 antagonist, glibenclamide, reduces hemorrhagic transformation and plasma MMP-9, but the mechanism is unknown.	Glyburide	85-98	matrix metallopeptidase 9	Homo sapiens	146-151	
24072459-7	2014	RESULTS: We report that IV glyburide was associated with T2 fluid-attenuated inversion recovery signal intensity ratio on brain MRI, diminished the lesional water diffusivity between days 1 and 2 (pseudo-normalization), and reduced blood MMP-9 level.	Glyburide	27-36	matrix metallopeptidase 9	Homo sapiens	238-243	
22994227-3	2012	Glyburide inhibits activation of MMP-9, ameliorates edema formation, swelling, and symptomatic hemorrhagic transformation, and improves preclinical outcomes in several clinically relevant models of stroke, both without and with rt-PA treatment.	Glyburide	0-9	matrix metallopeptidase 9	Homo sapiens	33-38	
30147301-7	2018	Additionally, recent work linked SUR1-TRPM4 to secretion of matrix metalloproteinase-9 (MMP-9) induced by recombinant tissue plasminogen activator in activated brain endothelial cells, with blockade of SUR1-TRPM4 by glyburide reducing MMP-9 and hemorrhagic transformation in preclinical models with recombinant tissue plasminogen activator.	Glyburide	216-225	matrix metallopeptidase 9	Homo sapiens	60-86	
30147301-7	2018	Additionally, recent work linked SUR1-TRPM4 to secretion of matrix metalloproteinase-9 (MMP-9) induced by recombinant tissue plasminogen activator in activated brain endothelial cells, with blockade of SUR1-TRPM4 by glyburide reducing MMP-9 and hemorrhagic transformation in preclinical models with recombinant tissue plasminogen activator.	Glyburide	216-225	matrix metallopeptidase 9	Homo sapiens	88-93	
30147301-8	2018	The recently completed GAMES (Glyburide Advantage in Malignant Edema and Stroke) clinical trials on patients with large hemispheric infarctions treated with intravenous glyburide (RP-1127) revealed promising findings with regard to brain swelling (midline shift), MMP-9, functional outcomes and mortality.	Glyburide	30-39	matrix metallopeptidase 9	Homo sapiens	264-269	
30147301-8	2018	The recently completed GAMES (Glyburide Advantage in Malignant Edema and Stroke) clinical trials on patients with large hemispheric infarctions treated with intravenous glyburide (RP-1127) revealed promising findings with regard to brain swelling (midline shift), MMP-9, functional outcomes and mortality.	Glyburide	169-178	matrix metallopeptidase 9	Homo sapiens	264-269	
30446594-8	2018	In the subset of patients with malignant edema, those treated with IV glyburide had less midline shift (p < 0.01) and reduced MMP-9 (matrix metalloproteinase 9) levels (p < 0.01).	Glyburide	70-79	matrix metallopeptidase 9	Homo sapiens	129-134	
30446594-8	2018	In the subset of patients with malignant edema, those treated with IV glyburide had less midline shift (p < 0.01) and reduced MMP-9 (matrix metalloproteinase 9) levels (p < 0.01).	Glyburide	70-79	matrix metallopeptidase 9	Homo sapiens	136-162	
29789393-11	2018	Participants treated with intravenous glyburide had lower plasma levels of MMP-9 (189 versus 376 ng/mL; P<0.001) and decreased midline shift (4.7 versus 9 mm; P<0.001) compared with participants who received placebo.	Glyburide	38-47	matrix metallopeptidase 9	Homo sapiens	75-80